nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Uremia—Lisinopril—systemic scleroderma	0.0385	0.0385	CcSEcCtD
Cisatracurium Besylate—Uremia—Mycophenolate mofetil—systemic scleroderma	0.0338	0.0338	CcSEcCtD
Cisatracurium Besylate—Trauma—Mometasone—systemic scleroderma	0.0329	0.0329	CcSEcCtD
Cisatracurium Besylate—Hypoxemia—Methotrexate—systemic scleroderma	0.0241	0.0241	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Lisinopril—systemic scleroderma	0.0183	0.0183	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Mycophenolate mofetil—systemic scleroderma	0.016	0.016	CcSEcCtD
Cisatracurium Besylate—Wheezing—Mometasone—systemic scleroderma	0.0152	0.0152	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Pentoxifylline—systemic scleroderma	0.0136	0.0136	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Leflunomide—systemic scleroderma	0.0129	0.0129	CcSEcCtD
Cisatracurium Besylate—Injury—Mometasone—systemic scleroderma	0.0124	0.0124	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Mycophenolic acid—systemic scleroderma	0.0123	0.0123	CcSEcCtD
Cisatracurium Besylate—Myopathy—Mycophenolate mofetil—systemic scleroderma	0.0122	0.0122	CcSEcCtD
Cisatracurium Besylate—Trauma—Prednisone—systemic scleroderma	0.0121	0.0121	CcSEcCtD
Cisatracurium Besylate—Laryngospasm—Mycophenolate mofetil—systemic scleroderma	0.0114	0.0114	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Pentoxifylline—systemic scleroderma	0.0112	0.0112	CcSEcCtD
Cisatracurium Besylate—Wheezing—Mycophenolic acid—systemic scleroderma	0.0105	0.0105	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Captopril—systemic scleroderma	0.0103	0.0103	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Mycophenolate mofetil—systemic scleroderma	0.00971	0.00971	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Mometasone—systemic scleroderma	0.00966	0.00966	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Captopril—systemic scleroderma	0.00949	0.00949	CcSEcCtD
Cisatracurium Besylate—Wheezing—Lisinopril—systemic scleroderma	0.00946	0.00946	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Methotrexate—systemic scleroderma	0.00907	0.00907	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Captopril—systemic scleroderma	0.0088	0.0088	CcSEcCtD
Cisatracurium Besylate—Injury—Mycophenolic acid—systemic scleroderma	0.00854	0.00854	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Leflunomide—systemic scleroderma	0.0085	0.0085	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Captopril—systemic scleroderma	0.00848	0.00848	CcSEcCtD
Cisatracurium Besylate—Flushing—Pentoxifylline—systemic scleroderma	0.00845	0.00845	CcSEcCtD
Cisatracurium Besylate—Myopathy—Prednisone—systemic scleroderma	0.00825	0.00825	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Pentoxifylline—systemic scleroderma	0.00823	0.00823	CcSEcCtD
Cisatracurium Besylate—Erythema—Pentoxifylline—systemic scleroderma	0.00793	0.00793	CcSEcCtD
Cisatracurium Besylate—Injury—Lisinopril—systemic scleroderma	0.00769	0.00769	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—systemic scleroderma	0.00761	0.00761	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Mycophenolic acid—systemic scleroderma	0.00746	0.00746	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Lisinopril—systemic scleroderma	0.0073	0.0073	CcSEcCtD
Cisatracurium Besylate—Angioedema—Pentoxifylline—systemic scleroderma	0.00725	0.00725	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Mometasone—systemic scleroderma	0.0071	0.0071	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Mometasone—systemic scleroderma	0.00708	0.00708	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Mycophenolic acid—systemic scleroderma	0.00692	0.00692	CcSEcCtD
Cisatracurium Besylate—Convulsion—Pentoxifylline—systemic scleroderma	0.00687	0.00687	CcSEcCtD
Cisatracurium Besylate—Hypertension—Pentoxifylline—systemic scleroderma	0.00685	0.00685	CcSEcCtD
Cisatracurium Besylate—Injury—Mycophenolate mofetil—systemic scleroderma	0.00674	0.00674	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Lisinopril—systemic scleroderma	0.00672	0.00672	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00671	0.00671	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00647	0.00647	CcSEcCtD
Cisatracurium Besylate—Flushing—Captopril—systemic scleroderma	0.00641	0.00641	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Pentoxifylline—systemic scleroderma	0.00632	0.00632	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Pentoxifylline—systemic scleroderma	0.00629	0.00629	CcSEcCtD
Cisatracurium Besylate—Angioedema—Mometasone—systemic scleroderma	0.00625	0.00625	CcSEcCtD
Cisatracurium Besylate—Hypotension—Pentoxifylline—systemic scleroderma	0.00605	0.00605	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Lisinopril—systemic scleroderma	0.00601	0.00601	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Mycophenolate mofetil—systemic scleroderma	0.00589	0.00589	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00577	0.00577	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Leflunomide—systemic scleroderma	0.00559	0.00559	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mometasone—systemic scleroderma	0.00558	0.00558	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Mycophenolic acid—systemic scleroderma	0.00553	0.00553	CcSEcCtD
Cisatracurium Besylate—Angioedema—Captopril—systemic scleroderma	0.00549	0.00549	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Mycophenolate mofetil—systemic scleroderma	0.00546	0.00546	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Azathioprine—systemic scleroderma	0.00544	0.00544	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Azathioprine—systemic scleroderma	0.00543	0.00543	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00533	0.00533	CcSEcCtD
Cisatracurium Besylate—Urticaria—Pentoxifylline—systemic scleroderma	0.00514	0.00514	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Leflunomide—systemic scleroderma	0.00514	0.00514	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Leflunomide—systemic scleroderma	0.00513	0.00513	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mometasone—systemic scleroderma	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Lisinopril—systemic scleroderma	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00492	0.00492	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Captopril—systemic scleroderma	0.00491	0.00491	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.00489	0.00489	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Captopril—systemic scleroderma	0.00479	0.00479	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Hypotension—Captopril—systemic scleroderma	0.00458	0.00458	CcSEcCtD
Cisatracurium Besylate—Pruritus—Pentoxifylline—systemic scleroderma	0.00458	0.00458	CcSEcCtD
Cisatracurium Besylate—Injury—Prednisone—systemic scleroderma	0.00457	0.00457	CcSEcCtD
Cisatracurium Besylate—Flushing—Lisinopril—systemic scleroderma	0.00454	0.00454	CcSEcCtD
Cisatracurium Besylate—Angioedema—Leflunomide—systemic scleroderma	0.00453	0.00453	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Lisinopril—systemic scleroderma	0.00444	0.00444	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00443	0.00443	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00441	0.00441	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Captopril—systemic scleroderma	0.00437	0.00437	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00436	0.00436	CcSEcCtD
Cisatracurium Besylate—Hypertension—Leflunomide—systemic scleroderma	0.00428	0.00428	CcSEcCtD
Cisatracurium Besylate—Erythema—Lisinopril—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00421	0.00421	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00419	0.00419	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Azathioprine—systemic scleroderma	0.00416	0.00416	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mycophenolic acid—systemic scleroderma	0.00409	0.00409	CcSEcCtD
Cisatracurium Besylate—Rash—Pentoxifylline—systemic scleroderma	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mycophenolic acid—systemic scleroderma	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Pentoxifylline—systemic scleroderma	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00404	0.00404	CcSEcCtD
Cisatracurium Besylate—Hypotension—Azathioprine—systemic scleroderma	0.004	0.004	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.004	0.004	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Prednisone—systemic scleroderma	0.00399	0.00399	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Leflunomide—systemic scleroderma	0.00396	0.00396	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mometasone—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Leflunomide—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Leflunomide—systemic scleroderma	0.00393	0.00393	CcSEcCtD
Cisatracurium Besylate—Angioedema—Lisinopril—systemic scleroderma	0.00389	0.00389	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00389	0.00389	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00386	0.00386	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Cisatracurium Besylate—Hypotension—Leflunomide—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00376	0.00376	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00375	0.00375	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Prednisone—systemic scleroderma	0.0037	0.0037	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.00362	0.00362	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Leflunomide—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mycophenolic acid—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Cisatracurium Besylate—Rash—Mometasone—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mometasone—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Cisatracurium Besylate—Pruritus—Captopril—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00344	0.00344	CcSEcCtD
Cisatracurium Besylate—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00341	0.00341	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Lisinopril—systemic scleroderma	0.00339	0.00339	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Lisinopril—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Cisatracurium Besylate—Hypotension—Lisinopril—systemic scleroderma	0.00325	0.00325	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00323	0.00323	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00322	0.00322	CcSEcCtD
Cisatracurium Besylate—Urticaria—Leflunomide—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Azathioprine—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Lisinopril—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Rash—Captopril—systemic scleroderma	0.00309	0.00309	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Captopril—systemic scleroderma	0.00309	0.00309	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Leflunomide—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Prednisone—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Cisatracurium Besylate—Pruritus—Leflunomide—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Prednisone—systemic scleroderma	0.00285	0.00285	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Cisatracurium Besylate—Urticaria—Lisinopril—systemic scleroderma	0.00276	0.00276	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mycophenolic acid—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00271	0.00271	CcSEcCtD
Cisatracurium Besylate—Rash—Azathioprine—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Azathioprine—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Cisatracurium Besylate—Flushing—Prednisone—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Prednisone—systemic scleroderma	0.00263	0.00263	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Prednisone—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Lisinopril—systemic scleroderma	0.00256	0.00256	CcSEcCtD
Cisatracurium Besylate—Rash—Leflunomide—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Leflunomide—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Cisatracurium Besylate—Erythema—Prednisone—systemic scleroderma	0.00253	0.00253	CcSEcCtD
Cisatracurium Besylate—Pruritus—Lisinopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Cisatracurium Besylate—Rash—Mycophenolic acid—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Cisatracurium Besylate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Cisatracurium Besylate—Angioedema—Prednisone—systemic scleroderma	0.00231	0.00231	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Rash—Lisinopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Convulsion—Prednisone—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Lisinopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Hypertension—Prednisone—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Prednisone—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Prednisone—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Prednisone—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Prednisone—systemic scleroderma	0.002	0.002	CcSEcCtD
Cisatracurium Besylate—Rash—Mycophenolate mofetil—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Cisatracurium Besylate—Urticaria—Prednisone—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Prednisone—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Cisatracurium Besylate—Pruritus—Prednisone—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Cisatracurium Besylate—Rash—Prednisone—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Prednisone—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
